Aptose Biosciences Inc. (NASDAQ:APTO) CEO William G. Rice Purchases 100,000 Shares of Stock

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice acquired 100,000 shares of the stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $0.20 per share, with a total value of $20,000.00. Following the transaction, the chief executive officer now owns 613,252 shares of the company’s stock, valued at approximately $122,650.40. This trade represents a 19.48 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Aptose Biosciences Price Performance

APTO stock opened at $0.18 on Wednesday. The stock has a 50-day moving average price of $0.37 and a two-hundred day moving average price of $0.58. Aptose Biosciences Inc. has a 12-month low of $0.13 and a 12-month high of $2.91.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Analyst Upgrades and Downgrades

APTO has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on Aptose Biosciences in a research report on Thursday, November 21st. They issued a “hold” rating for the company. HC Wainwright lowered their price objective on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.